FY2027 Earnings Forecast for ACAD Issued By Leerink Partnrs

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) – Research analysts at Leerink Partnrs upped their FY2027 earnings per share (EPS) estimates for shares of ACADIA Pharmaceuticals in a report released on Wednesday, November 6th. Leerink Partnrs analyst M. Goodman now expects that the biopharmaceutical company will post earnings of $1.60 per share for the year, up from their previous estimate of $1.45. The consensus estimate for ACADIA Pharmaceuticals’ current full-year earnings is $0.51 per share.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last released its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $0.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.14 by $0.06. ACADIA Pharmaceuticals had a return on equity of 27.29% and a net margin of 13.83%. The company had revenue of $250.40 million for the quarter, compared to analysts’ expectations of $248.83 million. During the same quarter in the previous year, the firm posted ($0.40) EPS. The firm’s quarterly revenue was up 18.3% on a year-over-year basis.

Several other research firms have also recently issued reports on ACAD. Morgan Stanley cut ACADIA Pharmaceuticals from an “overweight” rating to an “equal weight” rating and dropped their target price for the stock from $28.00 to $20.00 in a research report on Wednesday, August 7th. Needham & Company LLC restated a “buy” rating and issued a $28.00 price target on shares of ACADIA Pharmaceuticals in a report on Thursday. Royal Bank of Canada lowered their price target on ACADIA Pharmaceuticals from $29.00 to $26.00 and set an “outperform” rating on the stock in a report on Wednesday, August 7th. Citigroup lowered their price target on ACADIA Pharmaceuticals from $30.00 to $23.00 and set a “buy” rating on the stock in a report on Thursday, August 8th. Finally, Raymond James restated a “market perform” rating on shares of ACADIA Pharmaceuticals in a report on Thursday, October 10th. Six investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $25.56.

ACADIA Pharmaceuticals Trading Up 2.7 %

NASDAQ ACAD opened at $17.66 on Friday. The business’s 50 day moving average is $15.45 and its two-hundred day moving average is $15.97. ACADIA Pharmaceuticals has a 12-month low of $14.15 and a 12-month high of $32.59. The stock has a market capitalization of $2.93 billion, a price-to-earnings ratio of 22.64 and a beta of 0.38.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Park Place Capital Corp purchased a new position in shares of ACADIA Pharmaceuticals in the 3rd quarter worth $25,000. Values First Advisors Inc. purchased a new position in shares of ACADIA Pharmaceuticals in the 3rd quarter worth $27,000. Covestor Ltd raised its position in shares of ACADIA Pharmaceuticals by 70.5% in the 1st quarter. Covestor Ltd now owns 2,032 shares of the biopharmaceutical company’s stock worth $38,000 after buying an additional 840 shares during the period. Headlands Technologies LLC purchased a new position in shares of ACADIA Pharmaceuticals in the 1st quarter worth $48,000. Finally, Quest Partners LLC raised its position in shares of ACADIA Pharmaceuticals by 42.3% in the 3rd quarter. Quest Partners LLC now owns 3,520 shares of the biopharmaceutical company’s stock worth $54,000 after buying an additional 1,047 shares during the period. 96.71% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other ACADIA Pharmaceuticals news, COO Brendan Teehan sold 9,534 shares of the stock in a transaction on Monday, August 19th. The stock was sold at an average price of $15.28, for a total transaction of $145,679.52. Following the transaction, the chief operating officer now owns 52,177 shares of the company’s stock, valued at $797,264.56. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. In other ACADIA Pharmaceuticals news, COO Brendan Teehan sold 9,534 shares of the stock in a transaction on Monday, August 19th. The stock was sold at an average price of $15.28, for a total transaction of $145,679.52. Following the transaction, the chief operating officer now owns 52,177 shares of the company’s stock, valued at $797,264.56. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Stephen Davis sold 31,747 shares of the stock in a transaction on Monday, August 19th. The stock was sold at an average price of $15.28, for a total value of $485,094.16. Following the transaction, the chief executive officer now directly owns 186,555 shares in the company, valued at approximately $2,850,560.40. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 51,014 shares of company stock valued at $779,494 in the last quarter. 28.30% of the stock is currently owned by company insiders.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.